(Sharecast News) - Trellus Health announced the signing of a 12-month contract with one of the world's largest clinical research organisations to deploy its Trellus TrialSet digital platform in two late-stage clinical trials on Friday, focused on immunology and inflammation.
The AIM-traded firm said the agreement marked its second deal with a leading CRO, and further strengthened its presence in the clinical trials sector, which Trellus has identified as a strategic growth area.

It said the contract, due to begin before the end of the year, included an upfront payment, a monthly management fee, and milestone-based payments linked to three performance indicators - the number of potential participants opting into the TrialSet programme, the increase in qualified candidates referred for screening, and the reduction in screen failure rates.

Trellus said its TrialSet offering was designed to optimise recruitment by identifying individuals with lower resilience who may be reluctant to enrol in clinical trials, and by providing structured, evidence-based interventions to boost their readiness to participate.

"This represents another important milestone for Trellus Health®, underscoring the intrinsic value of our Trellus TrialSet digital solution and reflecting our continued focus on strategic execution," said chief executive Dr Marla Dubinsky.

"Since its launch earlier this summer, we have entered into two agreements with leading CROs, validating the relevance and differentiation of our offering.

"While the contract does not immediately extend the Company's current cash runway beyond early December 2025, combined with the Patient Support Program agreement signed with Johnson & Johnson in January which launched in the spring, these milestones demonstrate the growing recognition of the value Trellus Health delivers to the pharmaceutical sector.

"The company continues to explore options for a potential equity fundraising and further updates will be provided in due course, as appropriate."

At 0851 GMT, shares in Trellus Health were down 9.15% at 0.5p.

Reporting by Josh White for Sharecast.com.

• News Channel